CHMP anbefaler derfor, at kontraindkationen for patienter med hypertension skærpes, og at de ordinerende læger skal advares om, at patientens blodtryk skal overvåges, især i de første to uger efter behandlingsstart.
The CHMP therefore recommends the strengthening of the contraindication in hypertensive patients and alerts prescribers that blood pressure needs to be monitored, especially within 2 weeks of treatment initiation.